These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 8146779)
1. [The use of the preparation bonefos in the combined therapy of multiple myeloma patients]. Abdulkadyrov KM; Bessmel'tsev SS Ter Arkh; 1993; 65(12):70-2. PubMed ID: 8146779 [TBL] [Abstract][Full Text] [Related]
2. [The effect of clodronate on bone density in patients with multiple myeloma--a 2-year follow-up of therapeutic effects]. Adam Z; Prokes B; Znojĭl V; Vorlícek J; Hejlová N; Hájek D; Krejcí M Vnitr Lek; 1996 Jun; 42(6):379-85. PubMed ID: 8928406 [TBL] [Abstract][Full Text] [Related]
3. [A questionnaire survey of tolerance and adverse effects of clodronate (Bonefos) in patients with multiple myeloma]. Lastůvková I; Adam Z Vnitr Lek; 2002 Nov; 48(11):1049-53. PubMed ID: 12577456 [TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777 [TBL] [Abstract][Full Text] [Related]
5. [Effect of clodronate in patients with multiple myeloma. Evaluation of specific markers of bone resorption]. Slabý J; Spicka I; Hulejová H; Spacek P; Cieslar P; Klener P Cas Lek Cesk; 1997 Jan; 136(2):57-60. PubMed ID: 9147856 [TBL] [Abstract][Full Text] [Related]
6. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI) and methyl-prednisolone (HLBI-mP) in multiple myeloma]. Fukuzawa Y; Kawamura T; Ohno R Gan To Kagaku Ryoho; 1989 Nov; 16(11):3581-6. PubMed ID: 2817909 [TBL] [Abstract][Full Text] [Related]
7. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438 [TBL] [Abstract][Full Text] [Related]
9. [Skeletal bone lesion and the effectiveness of Bonephos (clodronate) in the comprehensive therapy of multiple myeloma]. Bessmel'tsev SS; Abdulkadyrov KM Vopr Onkol; 1996; 42(4):12-8. PubMed ID: 8928450 [No Abstract] [Full Text] [Related]
10. [The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction]. Golenkov AK; Lutskaia TD; Kliushnenkova EN; Tishenina RS; Valiulina LS; Novikov VE; Mitina TA Ter Arkh; 1996; 68(7):58-61. PubMed ID: 8928074 [TBL] [Abstract][Full Text] [Related]
11. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Ciepłuch H; Baran W; Hellmann A Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079 [TBL] [Abstract][Full Text] [Related]
13. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Sondergaard TE; Pedersen PT; Andersen TL; Søe K; Lund T; Ostergaard B; Garnero P; Delaisse JM; Plesner T Hematol Oncol; 2009 Mar; 27(1):17-22. PubMed ID: 18668701 [TBL] [Abstract][Full Text] [Related]
14. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Rajkumar SV; Richardson PG; Lacy MQ; Dispenzieri A; Greipp PR; Witzig TE; Schlossman R; Sidor CF; Anderson KC; Gertz MA Clin Cancer Res; 2007 Oct; 13(20):6162-7. PubMed ID: 17947482 [TBL] [Abstract][Full Text] [Related]
15. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429 [TBL] [Abstract][Full Text] [Related]
16. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
17. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105 [TBL] [Abstract][Full Text] [Related]
18. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Montazeri AH; Erskine JG; McQuaker IG Eur J Haematol; 2007 Jul; 79(1):69-71. PubMed ID: 17598839 [TBL] [Abstract][Full Text] [Related]
19. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Wang M; Weber DM; Delasalle K; Alexanian R Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221 [TBL] [Abstract][Full Text] [Related]
20. [New protocols for myeloma chemotherapy plus IFN alpha]. Kitani T Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]